delavirdine has been researched along with Acquired Immune Deficiency Syndrome in 11 studies
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Delavirdine doses were adjusted weekly until subjects were within their target trough concentration range (3 to 10, 11 to 30, or 31 to 50 microM)." | 2.69 | ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. ( Demeter, LM; Fischl, M; Freimuth, WW; Holden-Wiltse, J; Meehan, P; Morse, G; Nevin, T; Para, MF; Shafer, R; Virani-Ketter, N; Wood, K, 1999) |
| "Adult AIDS clinical trials units." | 2.69 | Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. ( Acosta, EP; Bassett, RL; Bell, D; Eron, JJ; Fife, K; Johnson, VA; Kuritzkes, DR; Marschner, IC; Martinez, A; Murphy, RL; Pettinelli, CB; Sommadossi, JP; Wood, K, 2000) |
| "Delavirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 (HIV-1) that is currently being evaluated in combination regimens with various nucleoside analogs, including didanosine." | 2.68 | Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ( Cox, SR; DeRemer, M; Driver, M; Fischl, MA; Freimuth, WW; Morse, GD; Shelton, MJ, 1997) |
| " To provide a rationale for combination therapy with a second-generation bisheteroarylpiperazine, we investigated the effect of U-90152 in combination with 3'-azido-3'-deoxythymidine (AZT) or 2',3'-dideoxycytidine (ddC)." | 1.29 | Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. ( Chong, KT; Hinshaw, RR; Pagano, PJ, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, ZY | 1 |
| Wei, HS | 1 |
| Zhao, HX | 1 |
| Liu, YN | 1 |
| Zhao, Y | 1 |
| Han, N | 1 |
| Cheng, J | 1 |
| Zhang, FJ | 1 |
| Chong, KT | 1 |
| Pagano, PJ | 1 |
| Hinshaw, RR | 1 |
| Morse, GD | 1 |
| Fischl, MA | 1 |
| Shelton, MJ | 1 |
| Cox, SR | 1 |
| Driver, M | 1 |
| DeRemer, M | 1 |
| Freimuth, WW | 2 |
| Esnouf, RM | 1 |
| Ren, J | 1 |
| Hopkins, AL | 1 |
| Ross, CK | 1 |
| Jones, EY | 1 |
| Stammers, DK | 1 |
| Stuart, DI | 1 |
| Para, MF | 1 |
| Meehan, P | 1 |
| Holden-Wiltse, J | 1 |
| Fischl, M | 1 |
| Morse, G | 1 |
| Shafer, R | 1 |
| Demeter, LM | 1 |
| Wood, K | 2 |
| Nevin, T | 1 |
| Virani-Ketter, N | 1 |
| Eng, KT | 1 |
| Liu, ES | 1 |
| Silverman, MS | 1 |
| Berger, AR | 1 |
| Kuritzkes, DR | 1 |
| Bassett, RL | 1 |
| Johnson, VA | 1 |
| Marschner, IC | 1 |
| Eron, JJ | 1 |
| Sommadossi, JP | 1 |
| Acosta, EP | 1 |
| Murphy, RL | 1 |
| Fife, K | 1 |
| Bell, D | 1 |
| Martinez, A | 1 |
| Pettinelli, CB | 1 |
| Campiani, G | 1 |
| Ramunno, A | 1 |
| Maga, G | 1 |
| Nacci, V | 1 |
| Fattorusso, C | 1 |
| Catalanotti, B | 1 |
| Morelli, E | 1 |
| Novellino, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)[NCT00000810] | Phase 1 | 120 participants | Interventional | Completed | |||
| Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects[NCT00000882] | Phase 2 | 300 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for delavirdine and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzodiazepinones; Benzoxazines; Cyclo | 2002 |
3 trials available for delavirdine and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Cross-Over Studies; Delavirdine; Didanos | 1997 |
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Dose- | 1999 |
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; C | 2000 |
7 other studies available for delavirdine and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Pharmacia pilots patent share for HIV drug.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Delavirdine; Drug Industry; Humans; Patents as | 2003 |
[HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Hi | 2007 |
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Drug Synergism; HIV Reverse Trans | 1994 |
[A new AIDS drug in evaluation].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Didanosine; Dose-Response Relatio | 1993 |
Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Delavirdine; Drug Resistance, Microbial; HIV Re | 1997 |
Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cholesterol; Delavirdine; Drug Therapy, Combination; HIV | 2000 |
FDA Advisory Committee stalemates on delavirdine.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Dis | 1997 |